EXACT Sciences Co. (NASDAQ:EXAS) had its price objective boosted by Roth Capital from $40.00 to $46.00 in a research note published on Wednesday, July 26th. They currently have a buy rating on the medical research company’s stock.
Other equities analysts have also recently issued reports about the company. Craig Hallum lifted their price objective on EXACT Sciences from $35.00 to $41.00 in a report on Friday, July 7th. Leerink Swann set a $38.00 price objective on EXACT Sciences and gave the stock a buy rating in a report on Friday, April 28th. Bank of America Corporation reaffirmed a buy rating on shares of EXACT Sciences in a report on Wednesday, March 29th. Jefferies Group LLC reaffirmed a buy rating and set a $25.00 price objective on shares of EXACT Sciences in a report on Wednesday, April 26th. Finally, Canaccord Genuity reaffirmed a buy rating and set a $27.00 price objective on shares of EXACT Sciences in a report on Monday, April 24th. Six investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. EXACT Sciences presently has a consensus rating of Buy and a consensus price target of $40.51.
EXACT Sciences (NASDAQ EXAS) traded up 1.92% during mid-day trading on Wednesday, hitting $37.76. The stock had a trading volume of 1,183,339 shares. The stock has a 50-day moving average price of $37.62 and a 200 day moving average price of $28.82. EXACT Sciences has a 12-month low of $13.05 and a 12-month high of $42.18. The firm’s market cap is $4.50 billion.
EXACT Sciences (NASDAQ:EXAS) last issued its quarterly earnings data on Tuesday, July 25th. The medical research company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.10. The firm had revenue of $57.65 million during the quarter, compared to analysts’ expectations of $47.73 million. EXACT Sciences had a negative return on equity of 29.05% and a negative net margin of 53.41%. Equities analysts anticipate that EXACT Sciences will post ($1.18) EPS for the current fiscal year.
In other news, CFO Jeffrey Thomas Elliott sold 5,846 shares of EXACT Sciences stock in a transaction on Monday, July 31st. The stock was sold at an average price of $39.41, for a total value of $230,390.86. Following the completion of the sale, the chief financial officer now owns 19,861 shares of the company’s stock, valued at $782,722.01. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP D Scott Coward sold 1,987 shares of EXACT Sciences stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $35.21, for a total value of $69,962.27. Following the completion of the sale, the senior vice president now directly owns 57,603 shares of the company’s stock, valued at approximately $2,028,201.63. The disclosure for this sale can be found here. 4.00% of the stock is owned by insiders.
Large investors have recently made changes to their positions in the stock. Fortaleza Asset Management Inc. acquired a new stake in shares of EXACT Sciences during the second quarter worth approximately $106,000. Northwestern Mutual Wealth Management Co. increased its stake in shares of EXACT Sciences by 17.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 4,072 shares of the medical research company’s stock worth $144,000 after buying an additional 600 shares in the last quarter. Financial Architects Inc increased its stake in shares of EXACT Sciences by 90.0% in the second quarter. Financial Architects Inc now owns 4,295 shares of the medical research company’s stock worth $152,000 after buying an additional 2,035 shares in the last quarter. Johnson Financial Group Inc. increased its stake in shares of EXACT Sciences by 25.9% in the second quarter. Johnson Financial Group Inc. now owns 4,862 shares of the medical research company’s stock worth $172,000 after buying an additional 1,000 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its stake in EXACT Sciences by 66.2% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,052 shares of the medical research company’s stock worth $179,000 after buying an additional 2,013 shares during the period. 84.86% of the stock is owned by institutional investors and hedge funds.
EXACT Sciences Company Profile
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.
Receive News & Ratings for EXACT Sciences Co. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for EXACT Sciences Co. and related companies with MarketBeat.com’s FREE daily email newsletter.
This post was originally published on *this site*